GeneDx Holdings Corp. (WGS)
| Market Cap | 1.91B |
| Revenue (ttm) | 267.23M |
| Net Income (ttm) | -83.50M |
| Shares Out | 27.47M |
| EPS (ttm) | -3.16 |
| PE Ratio | n/a |
| Forward PE | 165.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 498,708 |
| Open | 69.64 |
| Previous Close | 68.26 |
| Day's Range | 68.60 - 72.04 |
| 52-Week Range | 2.85 - 98.87 |
| Beta | 2.09 |
| Analysts | Strong Buy |
| Price Target | 80.60 (+16.01%) |
| Earnings Date | Feb 18, 2025 |
About WGS
GeneDx Holdings Corp., a genomics company, provides personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company accelerate the use of genomics and leverage clinical data to enable precision medicine as the standard of care. It utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process DNA-containing samples, analyzes information about patient-specific genetic variation, and generates test reports for clinicians and their patient... [Read more]
Financial Performance
In 2023, GeneDx Holdings's revenue was $202.57 million, a decrease of -13.69% compared to the previous year's $234.69 million. Losses were -$175.77 million, -67.98% less than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price forecast is $80.6, which is an increase of 16.01% from the latest price.
News
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that, effective as of January 14, 2025,...
GeneDx Holdings: A Phenomenal Comeback With More Room To Run
GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts include t...
GeneDx Announces Preliminary 2024 Financial Results
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported preliminary financial results for the fourth quarter and full year of 2024.
GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx launches new telehealth testing pathway to connect parents directly with genetic experts to increase access to exome and genome testing.
GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, continues its investment in advancing scientific discovery through und...
GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating O...
GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 43rd A...
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced Biogen, Praxis Precision Medicines and Stoke Therapeutics as the founding partners to its Patient Access Program for epilepsy.
GeneDx to Participate in Upcoming Investor Conference
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in the Piper Sandler 36th Annual Healthcare Conference.
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GeneDx Discover, a first-of-its-kind data visualizatio...
GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, ...
New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the results of an extensive study shedding light on th...
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American Soci...
Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds
The precision medicine market is projected to grow from $91.72 billion in 2024 to $246.3 billion by 2033, fueled by advancements in genomic technologies. In the last year, Natera, Inc. and GeneDx Hold...
GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term
GeneDx Holdings Corp. stock has risen by a scarcely believable >3,000% across the past year. The company provides exome sequencing products that can be used to search for and diagnose hundreds of gene...
GeneDx Holdings Corp. (WGS) Q3 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Execu...
Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance
GeneDx Holdings WGS stock is trading higher on Tuesday.
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2024.
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that JAMA, the Journal of the American Medical Associa...
GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists
GeneDx Holdings Corp. leverages its genomic and data science expertise to provide precise medical diagnostics, focusing on rare diseases and pediatric exome/genome testing. The company's second-quarte...
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it has provided genomic newborn screenings (gNBS) for ...
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced it will release financial results for the third quarter of 2024 before the market opens on Tuesday, October 29, 2024.
GeneDx Holdings: Profits On The Horizon For AI Driven Health Platform
GeneDx Holdings is poised for profitability in the near future. GeneDx is benefitting from increased volume and improved average reimbursement rates. The company's double-digit revenue growth and soon...
GeneDx to Participate in Fall Investor Conferences
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that company management will participate in upcoming investor conferences this fall.